Karaaslan S.Oran B.Çalişkan U.Baysal T.Başpinar O.Taş A.2020-03-262020-03-2620031300-7777https://hdl.handle.net/20.500.12395/18692The use of high-dose intravenous immunoglobulin (IVIG) has greatly increased in the last years. With broader use of immunoglobulin, the numbers of reported side effects are also growing. IVIG have also been used in the treatment of myocarditis and dilated cardiomyopathy. Here we reported a child with presumed acute myocarditis who has developed severe hemolytic anemia following high-dose IVIG administration. As our knowledge, this is the first case report with myocarditis or dilated cardiomyopathy who developed hemolytic anemia following high-dose IVIG administration.eninfo:eu-repo/semantics/openAccessAnemiaCardiomyopathyHemolyticImmunoglobulin therapyArticle204237240Q3